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ABSTRACT
Gastroparesis is a condition characterized 
by delayed gastric emptying and the most 
common known underlying cause is diabetes 
mellitus. Symptoms include nausea, vomiting, 
abdominal fullness, and early satiety, which 
impact to varying degrees on the patient’s 
quality of life. Symptoms and deficits do not 
necessarily relate to each other, hence despite 
significant abnormalities in gastric emptying, 
some individuals have only minimal symptoms 
and, conversely, severe symptoms do not always 
relate to measures of gastric emptying. Prokinetic 
agents such as metoclopramide, domperidone, 
and erythromycin enhance gastric motility and 
have remained the mainstay of treatment for 
several decades, despite unwanted side effects 
and numerous drug interactions. Mechanical 
therapies such as endoscopic pyloric botulinum 
toxin injection, gastric electrical stimulation, 
and gastrostomy or jejunostomy are used in 
intractable diabetic gastroparesis (DG), refractory 
to prokinetic therapies. Mitemcinal and TZP‑101 
are novel investigational motilin receptor and 
ghrelin agonists, respectively, and show promise 
in the treatment of DG. The aim of this review 
is to provide an update on prokinetic and 
mechanical therapies in the treatment of DG.
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INTRODUCTION
Gastroparesis is characterized by a failure 
of normal gastric motility and emptying. The 
delay in gastric emptying leads to considerable 
morbidity due to nausea, vomiting, anorexia, 
and stomach fullness. Both type 1 and 2 diabetes 
mellitus are frequently associated with abnormal 
gastric motility,1,2 and are a recognized cause of 
gastroparesis. The relationship between delayed 
gastric emptying and symptoms is variable, and 
individuals with delayed gastric emptying may 
be asymptomatic. Cross‑sectional studies show 
that around 30%‑50% of those with type 1 and 
2 diabetes exhibit delayed gastric emptying.3,4
Paradoxically, however, in the early stages of 
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Dopamine is present in the gastrointestinal 
tract and inhibits gastrointestinal motility via 
the suppression of neuronal acetylcholine release 
by the D2 receptor.14 This mechanism has been 
exploited therapeutically and forms the mainstay 
for  therapeutic  strategies  using  prokinetic 
agents.  Additional  alternative  mechanisms 
include the direct effect of acute hyperglycemia 
causing a significant delay in gastric emptying,15 
by  inducing  motor  dysfunction;  therefore, 
improvement in glycemia can increase the rate 
of gastric emptying.16 In both healthy subjects 
and patients with type 1 diabetes, acute changes 
in glycemia with a lowering of blood glucose has 
been shown to affect gastric motor function.17,18 
Even physiological hyperglycemia of 8 mmol/L 
in healthy subjects and patients with type 1 
diabetes may prolong the gastric emptying time 
when compared with ~4 mmol/L. This suggests 
that glycemic control has a major role in gastric 
motor dysfunction. 
Other factors that may play an important role 
in altering gastric emptying are hyperinsulinemia 
and insulin resistance, body mass index (BMI), 
smoking, and gender.19‑22 The phenomenon of 
nitric oxide “blunting” may lead to defects in 
gastric accommodation as evidenced by sildenafil 
accelerating gastric emptying in experimental 
studies23  and  indeed  manifesting  as  an 
unwanted side effect of nausea in those taking 
phosphodiesterase type 5 (PDE5) inhibitors for 
erectile dysfunction. Abnormalities in glucagon 
homeostasis have also been implicated in the 
pathogenesis of DG.24,25 Iatrogenic exacerbations 
of gastroparesis by therapies for hyperglycemia 
may be precipitated by agents that interfere with 
the neuroendocrine axis. Nausea may occur 
with metformin and this may well be related 
to the recently reported effect of metformin 
inhibiting dipeptidyl peptidase‑4 (DPP‑4) and 
raising glucagon‑like peptide‑1 (GLP‑1).26 Of 
course, both nausea and vomiting are common 
type 2 diabetes, there may be an accelerated phase 
of gastric emptying and enhanced proximal 
contraction resulting in nausea in individuals 
without overt neuropathy.5,6  DG is a cause of   
significant morbidity in the form of recurrent 
nausea and vomiting in only a small minority of 
patients, whilst in others it may manifest simply 
as unpredictable hypo‑ and hyperglycemia with 
overall deranged glycemic control.7 Thus, the 
phenomenon of “gastric hypoglycemia” is well 
documented8,9 and may be an important cause 
of unexplained hypoglycemia in those who are 
classified as having brittle diabetes.9
MeChANISM Of GASTRIC eMpTyING 
AND The pAThOGeNeSIS Of DG
Normal  gastric  emptying  depends  on 
synchronized tonic actions of the fundus and 
antrum with inhibition of pyloric and duodenal 
contractions.10 Complex and highly integrated 
interactions occur between the gastric smooth 
muscle, myenteric plexus innervated by the vagal 
nerve, and gastric pacemaker cells (interstitial cells 
of Cajal [ICC]).11 The primary defects leading to 
abnormal gastric emptying are vagal autonomic 
neuropathy and probable ICC pathology.12,13 
Neuropathy with subsequent aberrant postprandial 
response to hyperglycemia reduces the frequency 
of  antral  contractions  and  causes  weak 
contractions of the proximal stomach. Glucose 
levels >140 mg/dL (~8 mmol/L) may diminish 
antral contractions and inhibit migratory motor 
complex (MMC) activity.7 It is the lack of phase 
3 of the MMC (during which ingestible solids are 
emptied into the duodenum) that leads to antral 
hypomotility in the fasting state, which ultimately 
leads to accumulation of large ingestible particles 
or bezoars. There is also excessive and prolonged 
tonic and phasic contractions of the pylorus, and 
this with the other mechanical abnormalities leads 
to delayed gastric emptying. 34 Diabetes Ther (2010)  1(1):32-43.
emptying and there has been some progress 
towards using a single standardized protocol,21,30 
although this is currently not uniformly accepted. 
Historically, there have been inconsistencies 
in  meal  preparations,  patient  positioning, 
frequency, and duration of imaging, hence the 
normal range of values.21 This posed problems 
in  the  interpretation  and  validation  of  the 
results, particularly from “outside” institutions. 
Limitations of other methods exist; breath tests 
assume normal small bowel and pulmonary 
function, the SmartPill is not widely available, 
and ultrasonography is operator dependent and 
generally only measures liquid emptying.21 The 
suggested standardized test is by scintigraphy, 
using a low‑fat, egg‑white meal with imaging at 
baseline, 1, 2, and 4 hours after ingestion.21
MANAGeMeNT
Key principles in the treatment of DG are 
the correction of exacerbating factors, which 
include  regulation  of  glycemia,  adequate 
nutritional support, and the use of prokinetic 
therapies, which have formed the cornerstone 
of treatment for DG.31 The aim of treatment is 
to alleviate symptoms, shorten gastric emptying 
time,  improve  the  nutritional  status  of  the 
with GLP‑1 analogs and are the most common 
causes  of  therapy  failure.24,25,27  Alternative 
diabetic agents that have also been implicated 
in  exacerbating  delayed  gastric  emptying 
are  the  amylinomimetic  therapies  such  as 
pramlintide28,29 (Table 1).
DIAGNOSIS
Although  this  review  concentrates  on 
medical  and  mechanical  therapies,  it  is 
important to highlight routine standards of 
care  when  diagnosing  DG.  Other  motility 
disorders  can  mimic  DG,  such  as  gastric 
outlet obstruction. Use of prokinetic therapy 
in  the  latter  may  significantly  exacerbate 
symptoms  and,  therefore,  it  is  important 
to  exclude  this  disorder  prior  to  initiating 
therapy.  An  esophagogastroduodenoscopy 
(EGD) or a barium meal should be performed 
prior  to  measurements  of  gastric  emptying 
by  scintigraphy,  13C‑acetate/13C‑octanoate 
breath test, or the SmartPill® device (SmartPill 
Inc., Buffalo, NY, USA). Other less commonly 
used  methods  include  ultrasonography  and 
electrogastrography (mainly for research). 
Gastric  emptying  scintigraphy  (GES)  is 
considered the standard for measuring gastric 
Table 1. Diabetes therapies, the effects on gastric emptying, and mechanism of action.
Drug Effect on gastric emptying and mechanism
Metformin Possibly delayed: due to DPP-4 inhibition (gastric emptying studies required for definitive 
assessment)
Sulfonylureas None
Glitazones None
α-Glucosidase inhibitors
(particularly arcabose)
Delayed: probably due to release of gut hormones including GLP-1 and CCK
Amylinomimetics Delayed: inhibition of vagal cholinergic function
GLP-1 analogs Delayed: inhibition of vagal cholinergic function and changes in neuroendocrine axis leading to 
reduced antroduodenal contractility
DPP-4 inhibitors None: presumably because of lower GLP-1 concentrations than in GLP-1 analogs
CCK=cholecystokinin; DPP-4=dipeptidyl peptidase-4; GLP-1=glucagon-like peptide-1.Diabetes Ther (2010)  1(1):32-43. 35
patient, and thus optimize glycemic control. As 
previously discussed, hyperglycemia itself may 
delay gastric emptying and adequate control of 
glycemia is recognized as an important facet in 
the management of DG. However, there is little 
evidence to indicate that prokinetic agents may 
improve glycemic control through improved 
gastric emptying.6
pROKINeTIC AGeNTS
Prokinetic agents are the mainstay of treatment 
for DG and their use dates back to the 1970s.32,33 
However, there is a paucity of longitudinal 
studies demonstrating long‑term effectiveness of 
prokinetic therapy. In part, this reflects the natural 
history of DG, which is often characterized by 
exacerbations and spontaneous remissions which 
do not require long‑term therapy.
Metoclopramide
The use of metoclopramide has waxed and 
waned,  particularly  with  the  approval  and 
subsequent withdrawal of cisapride.14 Of the 
prokinetic agents, only metoclopramide has 
been licensed for use by the Food and Drug 
Administration (FDA) in DG. It is a potent central 
and peripheral dopamine‑receptor (specifically 
D2 receptor) and to a lesser extent serotonin 
antagonist34 acting on the brain stem and vagal 
nerves. It is thought to induce acetylcholine 
release from enteric neurons by antagonism of 
D2 receptors14 increasing antral contractions.35 
Several clinical trials of metoclopramide have 
shown it to be an effective short‑term therapy in 
DG,32‑35 although a longer duration of use may 
be associated with loss of gastrokinetic properties 
of the drug,36 but there is a lack of longitudinal 
data confirming this. Randomized studies of 
metoclopramide have shown improvement in 
gastric emptying,37‑40 but this correlates poorly 
with symptoms.39‑40 This poor correlation of 
symptoms with functional deficits is typical of 
DG, especially as those with severe symptoms 
may only have mild‑to‑moderate impairment of 
gastric emptying.41 Metoclopramide can cross the 
blood‑brain barrier accounting for its significant 
central nervous system (CNS) side effects, which 
include anxiety, agitation, somnolence, insomnia, 
and movement disorders with long‑term use, 
increasing the risk of developing intractable tardive 
dyskinesia (around 1%).42 Hence surreptitious 
use of this medication is recommended and it is 
approved by the FDA for short‑term (4‑12 weeks) 
use only.43 However, because DG is chronic, it is 
often prescribed indefinitely on an “as required” 
basis. Diabetes itself is a risk factor for tardive 
dyskinesia, along with female sex and younger 
age; the use of this drug,14 further enhances the 
likelihood of CNS side effects in DG.
Domperidone
Domperidone is another dopamine (D2)‑
receptor antagonist that antagonizes peripheral 
receptors,  particularly  in  the  stomach, 
leading to enhanced stomach contraction.11 
It does not cross the blood‑brain barrier and 
subsequently has a superior side‑effect profile 
to metoclopramide with a lack of CNS effects.44 
Indeed,  a  study  of  metoclopramide  versus 
domperidone by Patterson et al.44 showed a 
significantly reduced CNS side‑effect profile with 
domperidone, with greater tolerability but equal 
efficacy in improving symptoms. A number of 
studies over the past two decades have evaluated 
gastric emptying time, showing an improvement 
with  the  use  of  domperidone.45‑49  In  the 
systematic review by Sugumar et al. in 2008,49 
64% of studies showed significant efficacy for 
an improvement of symptoms, 60% showed 
an effect on gastric emptying, and 67% showed 
that domperidone effectively reduced hospital 36 Diabetes Ther (2010)  1(1):32-43.
admissions.  However,  the  methodological 
content of the evaluated studies was poor with a 
lack of a placebo control group in most studies.49 
At present, domperidone is not FDA approved for 
gastroparesis, and obtaining the drug for clinical 
practice in the US requires an investigational 
new drug application to the FDA.50  Dosing 
regimens and common side effects of dopamine 
(D2)‑receptor antagonists are detailed in Table 2, 
along with other prokinetic agents.
Erythromycin and Motilin Receptor Agonists
Erythromycin is a motilin receptor agonist 
that  is  associated  with  increased  antral 
contractions with improved gastric emptying,51,52 
particularly when administered intravenously.52 
Intravenous erythromycin is the drug of choice 
in  relieving  acute  gastroparesis  requiring 
hospitalization.50‑53  Dose  tolerance  may 
occur with chronic use,51 and also due to the 
interactions with cytochrome P450 CYP3A4 
inhibitors, it is not always a suitable therapy.11 
Other motilin agonists, such as azithromycin 
and clarithromycin, have been used but because 
they have not been extensively studied, they may 
be used only when gastroparesis symptoms are 
unresponsive to other prokinetics. Investigational 
motilin agonists, such as mitemcinal (GM‑611) 
and ABT‑229, lack the antibiotic activity of 
other drugs and have been assessed in clinical 
trials,54‑56 particularly as antibiotic resistance 
is  considered  to  be  of  concern  in  chronic 
erythromycin  use.57 However,  ABT‑229  has 
failed  to  effectively  control  gastroparesis 
symptoms  in  placebo‑controlled  trials.54,55 
A  study  of  mitemcinal  showed  a  disparity 
between gastroparesis symptoms and gastric 
emptying, as the latter was enhanced without a 
significant difference in symptom relief between 
the active compound and placebo.56 Mitemcinal 
may have a future role in the treatment of 
gastroparesis but requires further clinical trials to 
evaluate its safety and efficacy.
Table 2. Agents currently used in the treatment of diabetic gastroparesis.
Class of agent Name(s) Route (s) Dosing Side effects
Dopamine (D2)-receptor 
antagonists
Metoclopramide PO, IV, SC, IM 10 mg TDS/
QDS before 
meals
Anxiety, depression, extrapyramidal 
movement disorders, galactorrhoea, 
tardive dyskinesia
Domperidone PO 10-20 mg TDS 
before meals
Side effects listed above plus: 
abdominal cramps, irregular 
menstrual periods, loss of libido
Motilin-receptor agonists Erythromycin PO, IV 40-250 mg TDS 
before meals
Abdominal cramping, early satiety, 
urticaria, rashes
Clarithromycin PO 125-250 mg OD
Azithromycin PO 250 mg OD
Acetylcholinesterase 
inhibitors
Pyridostigmine PO 30 mg QDS Sweating, bladder dysfunction, 
increased production of saliva, 
diaphoresis, muscle weakness
IM=intramuscular; IV=intravenous; OD=once daily; PO=oral; QDS=four times daily; SC=subcutaneous; 
TDS=three times daily.Diabetes Ther (2010)  1(1):32-43. 37
Cisapride
Cisapride is a prokinetic agent that acts 
via 5‑HT4 receptors enhancing a cholinergic 
effect and inducing increased motor activity.58 
Previous studies comparing cisapride to other 
prokinetic  agents  have  shown  equivalent 
efficacy  with  both  erythromycin  and 
metoclopramide.54,55 Indeed, gastric emptying 
is improved with cisapride administration;59‑63 
however, due to safety concerns related to 
cardiac dysrhythmias, the drug was withdrawn 
from the USA14 and, subsequently, the UK 
in 2000. Tegaserod, another 5‑HT4‑receptor 
agonist used in DG, was again withdrawn due to 
cardiac safety concerns.
Ghrelin Agonists
Ghrelin  is  a  recently  discovered  peptide 
that stimulates growth hormone release.64‑67 
It  is  synthesized  in  endocrine  cells  in  the 
gastric mucosa61‑63 and is believed to exert the 
majority of its actions through the receptor 
GHSR‑1a,68 which mediates gastric motility and 
emptying with the induction of MMC.69 Ghrelin 
administration has been shown to enhance 
appetite and food intake70,71 but other non‑DG 
studies  have  shown  no  difference  between 
ghrelin and placebo.72 In a randomized, double‑
blind, crossover trial of ghrelin in DG by Murray 
et al.,73  gastric  emptying  was  increased  but 
did not always favorably improve symptoms, 
a phenomenon also common to trials with 
other prokinetic agents.54,56 Since the discovery 
of ghrelin, a number of molecularly similar 
receptor agonists have been used in clinical 
trials of gastrointestinal motility disorders.74‑76 
TZP‑101 is a selective intravenously administered 
agonist at the ghrelin receptor site. It appears 
to have a good safety profile in trials of healthy 
volunteers,77  and  has  also  been  shown  to 
be effective in enhancing gastric motility in 
DG75,76 and accelerating recovery in surgical 
postoperative  ileus.74  Furthermore,  an  oral 
preparation (TZP‑102) has been formulated, 
which is currently in phase 2 clinical trials. 
These novel ghrelin agonists show promise, 
particularly  in  view  of  the  relatively  poor 
side  effect  profiles  of  currently  licensed 
prokinetic therapies.
Other Prokinetic Agents
Other agents include muscarinic agonists 
and anticholinesterases such as bethanechol 
and pyridostigmine, respectively, and may be 
used in DG, but data assessing effects on gastric 
emptying are lacking.50
MeChANICAL TheRApIeS
A number of nonpharmacological treatments 
have been used with varying success in the 
management of DG. 
Acupuncture
The underlying mechanism of acupuncture in 
reducing symptoms of gastroparesis is unknown.10 
Efficacy has been reported for symptoms in a single‑
blind, randomized trial of electroacupuncture.78 
Dyspeptic symptoms were reduced and solid 
gastric emptying was accelerated. Further studies 
are required to investigate the possible benefits of 
acupuncture in DG.
Botulinum Toxin
Pylorospasm  (excessive,  prolonged 
contractions of the pylorus) is recognized as a 
manifestation of DG and has been investigated 
with antroduodenal manometry.79,80 Botulinum 
toxin  is  an  inhibitor  of  neuromuscular 38 Diabetes Ther (2010)  1(1):32-43.
transmission at cholinergic terminals,81 and 
has been used in achalasia.82 Whilst several 
uncontrolled studies have suggested efficacy,83 
two  previous  placebo‑controlled  trials  have 
not shown superiority of botulinum toxin over 
placebo in managing DG.84,85 Neither study 
had antroduodenal manometry, particularly 
considering  that  small  intestine  motor 
dysfunction  can  range  anywhere  from  17% 
to 85% in DG.83 Botulinum toxin may still 
be an effective therapy particularly in those 
with pylorospasm; however, routine use is not 
recommended at present. 
Gastric Pacing
Recently,  gastric  electrical  stimulation 
therapy (gastric pacing) has been approved 
by  the  FDA  (Enterra  therapy,  Medtronic, 
Minneapolis, MN, USA).4 The National Institute 
for  Health  and  Clinical  Excellence  (NICE) 
advises that gastric electrical stimulation is 
an option for the treatment of patients with 
chronic, intractable, drug‑refractory nausea and 
vomiting.86 Although patients suitable for this 
procedure are relatively uncommon, those with 
severe symptoms may well benefit.86 Gastric 
electrical stimulation delivers impulses at high 
frequency/low energy (short pulses) at around 
12 pulses per minute via a pacemaker. The 
device is implanted on the anterior abdominal 
wall and leads are implanted in the serosa of 
the greater curvature of the stomach. Both the 
severity and frequency of symptoms improved 
in open‑label studies, which were maintained 
for up to 4 years.87‑91 The underlying basis 
for improved symptoms has again not been 
consistently  related  to  accelerated  gastric 
emptying.88 Central effects and increases in 
postprandial gastric accommodation have been 
suggested, but the precise mechanism remains 
uncertain. Infection is the major complication 
of this treatment, requiring removal of the 
device in approximately 10% of patients.
Surgical Therapies
Surgical treatments may be used in those 
with  severe  intractable  DG  who  are  often 
hospitalized on multiple occasions. Gastrostomy 
may be used to alleviate severe symptoms such 
as nausea, vomiting, and bloating,92 although 
persistent symptoms may still exist despite 
surgery due to small bowel denervation and 
dysmotility.93 Jejunostomies  are  indicated 
to  maintain  fluid  balance  and  nutritional 
status,92  and  can  be  an  effective  “last 
resort”  measure.92  Interestingly,  pancreatic 
transplantation has been shown to benefit those 
with DG.94 Studies assessing neuropathy have 
shown early nerve fiber regeneration in type 1 
diabetic patients after pancreas transplantation,95 
and this may be the potential basis for relieving 
symptoms, but of course, overall improved 
glycemic control must play a role in improving 
gastric emptying.
CONCLUSION
The  rising  prevalence  of  diabetes  will 
inevitably result in increasing rates of chronic 
complications including gastroparesis. Patients 
develop a variety of symptoms that do not always 
correlate with the degree of abnormality on 
gastric emptying. Current treatment options are 
limited; however, novel investigational agents 
of the motilin and ghrelin class show promise. 
Intractable DG may require intervention with 
gastric electrical stimulation or surgery.
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